

Magdalena Kotlicka-Antczak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/361593/publications.pdf>

Version: 2024-02-01

31
papers

590
citations

686830

13
h-index

642321

23
g-index

31
all docs

31
docs citations

31
times ranked

925
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. <i>Journal of Psychiatric Research</i> , 2016, 73, 34-44.	1.5	88
2	Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence). <i>Frontiers in Psychiatry</i> , 2019, 10, 764.	1.3	72
3	Worldwide implementation of clinical services for the prevention of psychosis: The IEPA early intervention in mental health survey. <i>Microbial Biotechnology</i> , 2020, 14, 741-750.	0.9	58
4	Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. <i>BMC Psychiatry</i> , 2015, 15, 97.	1.1	41
5	Schizophrenia patients have higher-order language and extralinguistic impairments. <i>Schizophrenia Research</i> , 2018, 192, 274-280.	1.1	38
6	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2019, 10, 345.	1.3	29
7	Supplementation of antipsychotic treatment with sarcosine " GlyT1 inhibitor " causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. <i>Neuroscience Letters</i> , 2015, 606, 7-12.	1.0	28
8	PORT (Programme of Recognition and Therapy): the first Polish recognition and treatment programme for patients with an at-risk mental state. <i>Microbial Biotechnology</i> , 2015, 9, 339-342.	0.9	26
9	Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. <i>International Journal of Molecular Sciences</i> , 2015, 16, 24475-24489.	1.8	24
10	Obstetrical complications and Apgar score in subjects at risk of psychosis. <i>Journal of Psychiatric Research</i> , 2014, 48, 79-85.	1.5	22
11	Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. <i>Nutrients</i> , 2015, 7, 8767-8782.	1.7	22
12	Telomere length in blood cells is related to the chronicity, severity, and recurrence rate of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1493.	1.0	18
13	Overrated hedonic judgment of odors in patients with schizophrenia. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 1156-1162.	1.9	14
14	Polish individuals with an at-risk mental state: demographic and clinical characteristics. <i>Microbial Biotechnology</i> , 2018, 12, 391-399.	0.9	14
15	Deficits in the identification of pleasant odors predict the transition of an at-risk mental state to psychosis. <i>Schizophrenia Research</i> , 2017, 181, 49-54.	1.1	13
16	Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2022, 27, 3670-3678.	4.1	13
17	Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state. <i>European Psychiatry</i> , 2019, 58, 72-79.	0.1	9
18	Differences in omega-3 and omega-6 polyunsaturated fatty acid consumption in people at ultra-high risk of psychosis, first-episode schizophrenia, and in healthy controls. <i>Microbial Biotechnology</i> , 2017, 11, 498-508.	0.9	8

#	ARTICLE	IF	CITATIONS
19	A developmentally-stable pattern of premorbid schizoid-schizotypal features predicts psychotic transition from the clinical high-risk for psychosis state. <i>Comprehensive Psychiatry</i> , 2019, 90, 95-101.	1.5	8
20	<p>Odor perception and hedonics in chronic schizophrenia and in first episode psychosis</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 647-654.	1.0	8
21	Preliminary study of higher-order language and extralinguistic impairments in individuals with high clinical risk of psychosis and first episode of schizophrenia. <i>Microbial Biotechnology</i> , 2019, 13, 369-378.	0.9	8
22	Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 533.	1.0	5
23	<p>The Relationship Between Course of Illness and Î²-Endorphin Plasma Levels in Patients with Schizophrenia</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 3609-3614.	1.0	5
24	Figural fluency and immediate visual memory in patients with at-risk mental state for psychosis: empirical study. <i>Microbial Biotechnology</i> , 2015, 9, 324-330.	0.9	4
25	A history of obstetric complications is associated with the risk of progression from an at risk mental state to psychosis. <i>Schizophrenia Research</i> , 2018, 197, 498-503.	1.1	4
26	Higher order language impairments can predict the transition of ultrahigh risk state to psychosisâ€”An empirical study. <i>Microbial Biotechnology</i> , 2021, 15, 314-327.	0.9	3
27	The Relationship Between Antipsychotic Treatment and Plasma Î²-Endorphin Concentration in Patients with Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 503-512.	1.0	3
28	Plasma Î²-Endorphin Concentration and Antipsychotic Treatment Outcome in Schizophrenia: 1-Year Follow-Up. <i>Medical Science Monitor</i> , 2020, 26, e924307.	0.5	3
29	Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. 1H-NMR Spectroscopy Study. <i>International Journal of Molecular Sciences</i> , 2015, 16, 24387-24402.	1.8	1
30	Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study). <i>Human Psychopharmacology</i> , 2021, 36, e2770.	0.7	1
31	Plasma Î²-Endorphin Concentration and Antipsychotic Treatment Outcome in Schizophrenia: 1-Year Follow-Up. <i>Medical Science Monitor</i> , 2020, 26, e924307.	0.5	0